Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript

1mon ago, source: InvestingChannel on MSN

Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript March 5, 2024 Plus Therapeutics, Inc. beats earnings ...

Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team

6d ago, source:

The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will ...

Buy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry Tailwinds

24d ago, source: Business Insider

Plus Therapeutics (PSTV) Company Description: Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and manufacturing scale up of complex and ...

Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic

22d ago, source: Stockhouse

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for ...

Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases

1mon ago, source: Stockhouse

AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted ...

Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer

13h ago, source:

Candel Therapeutics, Inc. has done well to advance its main drug CAN-2409 for the treatment of patients with several types of ...

Cancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing Data

on MSN ago, source:

Thursday, eFFECTOR Therapeutics Inc (NASDAQ:EFTR) released topline results from the primary analysis of the Phase 2 KICKSTART ...

Plus Therapeutics, Inc. (PSTV) Q4 2023 Earnings Call Transcript

1mon ago, source: Seeking Alpha

Good afternoon, ladies and gentlemen. Welcome to the Plus Therapeutics Fourth Quarter and Full Year 2023 Results Conference Call. [Operator Instructions] Please be advised that today's conference ...

Plus Therapeutics Inc PSTV

5d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript

1mon ago, source: Insider Monkey

Sean Lee: Great. Thanks for the clarification. And as a follow-up on that, for the potential future pivotal study that’s coming next year, do you see CNS side serving as a primary endpoint for ...